Navigation auf uzh.ch
Navigation auf uzh.ch
OnTrack Biomedical AG is a UZH MedTech company that develops in-vitro diagnostic tests for the non-invasive early detection and monitoring of prostate cancer. ONtrack Biomedical was awarded the UZH Startup Label in 2024.
The first product in the pipeline of the MedTech spin-off from the University of Zurich and University Hospital Zurich is called PROBAN, a urine test that facilitates the early detection of prostate cancer. The aim is to spare men an unnecessary prostate biopsy, which was previously considered standard due to unspecifically high serum PSA levels. At the same time, a cost-effective in-vitro test can be used more frequently to ensure that those men who have a prostate tumour do not miss the opportunity of early detection.
OnTrack Biomedical was founded in January 2023. The academic project behind PROBAN was launched in 2018 at the University of Zurich with ONtrack Diagnostics and supported by funding. The team is made up of experienced scientists, clinicians and entrepreneurs. ONTRACK Biomedical builds on an innovative research and development platform and comprehensive expertise in the field of medical technology. ONtrack Biomedical received the UZH Startup Label in 2024.
Since 1999, more than 100 spin-offs have been founded at the University of Zurich that develop new products based on UZH technologies or bring them to market maturity. Since 2017, UZH has been awarding selected spin-offs and start-ups the "UZH Startup Label".
With the UZH Startup Label, companies become part of an innovative community at the University of Zurich; founders can also officially communicate as a UZH Startup and benefit from recognition by the University of Zurich.
